Pfizer, Inc. (PFE)

NYSE · Drug Manufacturers - General

26.76
+0.56 (+2.14%)
Updated Aug 8, 2:10 PM ET
AI Rating
Hold
Overall Score
49
Trend
3
Momentum
68
Risk
96

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Jul 22, 2025 260 sessions Aug 3, 2026

AI Analysis

Pfizer, Inc. is trading at $26.76, up 2.14% on the session. The 50 day average sits at $25.07 and the 200 day at $25.83, which puts the stock in a downtrend. RSI is at 51.4, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $24.44 with resistance near $25.50, so that band frames the current range. Average daily movement is roughly $0.51, or about 1.9% of the share price, which is what any stop placement has to allow for. The overall health score of 49 out of 100 combines a trend score of 3, momentum of 68 and a risk score of 96.

Technical indicators

RSI (14)
51.4
neutral
MACD
0.031
bullish crossover
SMA 20
24.71
SMA 50
25.07
SMA 200
25.83
downtrend
ATR (14)
0.51
avg daily range
Support
24.44
Resistance
25.50
Volume vs 20d
0.52x
below average
Volatility
18.1%
annualised
1 month
+2.59%
3 months
-5.24%

About Pfizer, Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.